Healthcare

May 27, 2015

1

Pharmaceutical industry: Pharma Group aims to strengthen investments in Algeria

Pharmaceutical company "Pharma group" aims "to strengthen its investments in Algeria" for the "very favorable" conditions, Group representative, Samir Khelil said Tuesday.


"Algeria is a promising market for Pharma group companies in the MENA region (Middle East and North Africa), especially since the conditions are very favorable," Khelil said after his meeting with"...

Continue Reading >

May 27, 2015

2

H.E Mr. Abdulla bin Khalid Al-Qahtani, Minister of Public Health & Secretary General of the Supreme Council of Health (SCH) inaugurates

The Qatar International Medical Congress (QIMC) 2015


Under the patronage of the Prime Minister of Qatar and Minister of Interior, HE Sheikh Abdullah bin Nasser bin Khalifa Al Thani .. H.E Mr. Abdulla bin Khalid Al-Qahtani, Minister of Public Health & Secretary General of the Supreme Council of Health (SCH) inaugurated QIMC 2015 at the Qatar National Convention Centre"...

Continue Reading >

May 27, 2015

3

Jawaher Al Qasimi Helps Save Lives of 30,000 Kids Yearly Through Cancer Fund

An International Childhood Cancer Fund (ChiCa) has been launched by Her Highness Sheikha Jawaher bint Mohammed Al Qasimi, Wife of His Highness the Ruler of Sharjah, Founder and Royal Patron of the Friends of Cancer Patients Society (FoCP), the International Ambassador of the World Cancer Declaration for Union for International Cancer Control (UICC), and International Ambassador for Childhood Cancer for UICC.


The"...

Continue Reading >

May 25, 2015

4

Moroccan e-health platform DabaDoc expands to Algeria, Tunisia

Moroccan startup DabaDoc, which allows users to find doctors and book appointments online, has expanded to Algeria and Tunisia, with the platform now supporting over 2,000 doctors in the three countries.


Launched early last year by Zineb Yacoubi and Driss Kaitouni, DabaDoc allows thousands of patients each month to connect"...

Continue Reading >

May 19, 2015

5

TIELLE® Non Adhesive Foam Dressing Now Available from Acelity

Acelity, a global wound care and regenerative medicine company, today announced that TIELLE® Non Adhesive, a new and improved foam dressing, is now available in Europe. TIELLE® Non Adhesive is the first in an enhanced range of TIELLE® hydropolymer foam dressings incorporating new design and materials to better meet patient needs and help provide a comfortable and effective healing environment for all types of wounds.


The TIELLE®"......

Continue Reading >

May 19, 2015

6

Analysis of Phase II Data for Celgene’s Investigational Oral GED-0301 in Patients with Active Crohn’s Disease Presented at Digestive Disease Week

Celgene Corporation (NASDAQ: CELG) today announced that a post-hoc subgroup analysis of a double-blind, placebo-controlled, randomized, multicenter phase II trial of GED-0301 (mongersen) in patients with active Crohn's disease was presented at Digestive Disease Week (DDW) in Washington, D.C.


“For patients with Crohn’s, disease severity and duration can influence"...

Continue Reading >

May 18, 2015

7

Boehringer Ingelheim acquires Pharmaxis’ phase 1 anti-inflammatory drug candidate

  • Boehringer Ingelheim exercises option and acquires global ownership of Pharmaxis’ investigational anti-inflammatory drug candidate PXS4728A, including associated intellectual property rights.
  • PXS4728A is a highly selective oral small molecule inhibitor of vascular adhesion protein-1 that has shown activity in pre-clinical investigation in non-alcoholic steatohepatitis (NASH).
  • Drug candidate will be investigated for the treatment of NASH and has further potential in chronic obstructive pulmonary disease (COPD) and other diseases with high medical need.
  • The...

    Continue Reading >

May 18, 2015

8

New data and analyses confirm the efficacy and safety of OFEV® (nintedanib*) for the treatment of IPF beyond 52 weeks and for distinct subgroups

  • Effect of nintedanib* on slowing disease progression was maintained for up to 76 weeks in the TOMORROW trial
  • Long-term nintedanib* treatment in the INPULSIS®-ON extension study confirms manageable safety and tolerability profile for up to 33 months
  • Pooled analyses confirm efficacy of nintedanib* in patients with early IPF disease (forced vital capacity (FVC) > 90% predicted at baseline)
  • Nintedanib* is the first targeted treatment for IPF to consistently demonstrate its efficacy in two identically designed Phase III trials and these long-term and pooled...

    Continue Reading >

May 14, 2015

9

Boehringer Ingelheim showcases expanding presence in lung cancer at ASCO 2015 with new data including presentation of afatinib* overall survival results for squamous cell carcinoma of the lung

• LUX-Lung 8 Phase III study evaluating the efficacy and safety of afatinib* vs. erlotinib for patients with advanced squamous cell carcinoma of the lung met secondary endpoint of overall survival


• 9 abstracts accepted including latest data for afatinib* and nintedanib** in lung cancer and beyond


...

Continue Reading >

May 12, 2015

10

Dr. Michael’s Dental Clinic in Dubai Welcomes New Dentist

Dr. Michael’s Dental Clinic, the leading and most advanced dental health care provider in the region, welcomes Dr. Ines Sandhof to its team. Dr. Ines is a licensed GP dentist in Dubai and Germany with 14 years of extensive private practice.


“From a very young age I was fascinated by art, science in general and medicine in particular,” said Dr. Ines. “I"...

Continue Reading >